

Press release 2026-03-05

AcuCort to participate in Bio Europe Spring – focus on international partnerships

Swedish pharmaceutical company AcuCort will participate in the international partnering conference BIO Europe Spring, taking place from 23–25 March 2026 in Portugal. The participation forms part of the company’s broader strategy to advance its business development activities and establish new commercial partnerships.

BIO Europe Spring is one of the leading global partnering conferences within the life sciences sector, offering structured one-to-one partnering meetings with prospective partners. The conference provides AcuCort with the opportunity to engage with international pharmaceutical companies that may become potential future distributors or licensees of the Company’s medicinal product, Zeqmelit®.

“Partnering conferences are effective platforms for business development, enabling us to meet both new and existing contacts, advance ongoing discussions and gain valuable insight into current industry trends. In 2026, we look forward to a number of productive B2B meetings at these events,” says Jonas Jönmark, CEO of AcuCort.

AcuCort’s participation in Bio Europe Spring forms part of a broader programme of activities in 2026, encompassing both business development-focused and therapy area-specific events. As part of its business development initiatives, the Company also plans to attend the Bio International Convention in the United States and Bio Europe in Germany. These conferences provide opportunities for follow-up meetings throughout the year and may contribute to accelerating the process towards commercial agreements.

For further information:

Jonas Jönmark, CEO, AcuCort AB

Phone: 070 365 5400

E-mail: jonas.jonmark@acucort.se

About AcuCort AB (publ)

AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.